CRISPR Therapeutics General Counsel James R. Kasinger disposes of common shares worth $626,459.6

PUBT · 18h ago
CRISPR Therapeutics General Counsel James R. Kasinger disposes of common shares worth $626,459.6
  • James R. Kasinger, general counsel and secretary, sold 10,400 common shares on Sept. 22 at USD 60.2365.
  • Transaction followed an option exercise for 10,400 shares at USD 13.62 on the same day.
  • Directly held common shares fell to 94,784 following the transactions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-401237), on September 24, 2026, and is solely responsible for the information contained therein.